Volume 17, Number 6—June 2011
Dispatch
Klebsiella pneumoniae Bacteremia and Capsular Serotypes, Taiwan
Table A2
Distribution and clinical characteristics of 133 patients with community-onset Klebsiella pneumoniae bacteremia caused by different serotypes, Taiwan*
| Characteristic | K1 (n = 36) | K2 (n = 22) | Non-K1/K2 (n = 75) | Univariate analysis (K1 vs. non–K1/K2) |
Univariate analysis (K2 vs. non– K1/K2) |
||
|---|---|---|---|---|---|---|---|
| OR (95% CI) | p value | OR 95% CI | p value | ||||
| Age, y | 60.6 ± 13.5 | 58.0 ± 15.6 | 63.7 ± 16.6 | 0.99 (0.96–1.01) | 0.33 | 0.98 (0.95–1.01) | 0.13 |
| M:F | 23:13 | 15:7 | 40:35 | 1.55 (0.68–3.51) | 0.30 | 1.88 (0.69–5.12) | 0.22 |
| Severity of disease (McCabe classification) | |||||||
| Nonfatal | 29 (80.6) | 18 (81.8) | 51 (68.0) | 1.95 (0.75–5.078) | 0.17 | 2.12 (0.65–6.94) | 0.22 |
| Ultimately fatal | 5 (13.9) | 3 (13.6) | 17 (22.7) | 0.55 (0.19–1.63) | 0.28 | 0.54 (0.14–2.04) | 0.36 |
| Rapidly fatal | 2 (5.5) | 1 (4.6) | 7 (9.3) | 0.57 (0.11–2.90) | 0.50 | 0.46 (0.05–3.98) | 0.48 |
| Pittsburgh bacteremia score | 2.5 ± 2.7 | 3.2 ± 3.7 | 3.8 ± 4.6 | 0.91 (0.81–1.03) | 0.13 | 0.97 (0.86–1.09) | 0.60 |
| Underlying illness, condition, or value | |||||||
| Diabetes mellitus | 17 (47.2) | 11 (50.0) | 31 (41.3) | 1.27 (0.57–2.83) | 0.56 | 1.42 (0.55–3.68) | 0.47 |
| End-stage renal disease | 1 (2.8) | 0 | 5 (6.7) | 0.40 (0.05–3.56) | 0.41 | NA | NA |
| Heart disease | 3 (8.3) | 5 (22.7) | 13 (17.3) | 0.43 (0.12–1.63) | 0.22 | 1.49 (0.44–4.49) | 0.57 |
| Stroke | 3 (8.3) | 3 (13.6) | 9 (12.0) | 0.67 (0.17–2.63) | 0.56 | 1.16 (0.29–4.71) | 0.84 |
| Active malignancy | 3 (8.3) | 1 (4.6) | 12 (16.0) | 0.48 (0.13–1.81) | 0.28 | 0.25 (0.03–2.04) | 0.20 |
| Liver cirrhosis | 3 (8.3) | 3 (13.6) | 9 (12.0) | 0.67 (0.17–2.63) | 0.56 | 1.16 (0.29–4.71) | 0.84 |
| Surgery within 3 mo | 2 (5.6) | 0 | 10 (13.3) | 0.38 (0.08–1.85) | 0.23 | NA | NA |
| CT within 3 mo | 1 (2.8) | 0 | 3 (4.0) | 0.69 (0.07–6.83) | 0.75 | NA | NA |
| Creatinine level, mg/dL | 1.7 ± 2.0 | 1.5 ± 1.2 | 1.9 ± 2.1 | 0.95 (0.77–1.18) | 0.66 | 0.86 (0.62–1.19) | 0.35 |
| Albumin level, g/dL† | 2.7 ± 0.6 | 2.6 ± 0.4 | 2.9 ± 0.6 | 0.63 (0.23–1.67) | 0.35 | 0.33 (0.09–1.27) | 0.11 |
| Type of infection | |||||||
| Primary bacteremia | 8 (22.2) | 5 (22.7) | 18 (24.0) | 0.91 (0.35–2.33) | 0.84 | 0.93 (0.30–2.88) | 0.90 |
| Respiratory tract | 3 (8.3) | 4 (18.2) | 12 (16.0) | 0.48 (0.13–1.81) | 0.28 | 1.17 (0.34–4.06) | 0.81 |
| Urinary tract | 2 (5.6) | 3 (13.6) | 17 (22.7) | 0.20 (0.04–0.92) | 0.039 | 0.54 (0.14–2.04) | 0.36 |
| Biliary tract | 3 (8.3) | 2 (9.1) | 20 (26.7) | 0.25 (0.07–0.91) | 0.035 | 0.28 (0.06–1.28) | 0.10 |
| Liver abscess | 18 (50.0) | 5 (22.7) | 6 (8.0) | 11.5 (3.99–33.20) | <0.001 | 3.38 (0.92–12.4) | 0.07 |
| Intraabdominal | 1 (2.8) | 2 (9.1) | 1 (1.3) | 2.1 (0.13–34.80) | 0.60 | 7.40 (0.64–85.82) | 0.11 |
| Soft tissue | 0 | 0 | 1 (1.3) | NA | NA | NA | NA |
| Meningitis | 1 (2.8) | 1 (4.6) | 0 | NA | NA | NA | NA |
| TTP, h | 13.6 ± 17.4 | 10.4 ± 3.0 | 15.6 ± 21.1 | 0.99 (0.97–1.02) | 0.62 | 0.97 (0.90–1.04) | 0.34 |
| TTP<7 h | 5 (13.9) | 2 (9.1) | 8 (10.7) | 1.35 (0.41–4.47) | 0.62 | 0.84 (0.34–2.09) | 0.71 |
| 14-d mortality rate | 3 (8.3) | 3 (13.6) | 13 (17.3) | 0.43 (0.12–1.63) | 0.22 | 0.75 (0.19–2.92) | 0.68 |
| In-hospital mortality rate | 5 (13.9) | 6 (27.3) | 21 (28.0) | 0.42 (0.14–1.21) | 0.11 | 0.96 (0.33–2.80) | 0.95 |
| ESBL-producing strain | 0 | 0 | 0 | NA | NA | NA | NA |
| Effective empirical agent | 31 (86.1) | 22 (100.0) | 72 (96.0) | 0.26 (0.06–1.15) | 0.08 | NA | NA |
*Values are mean ± SD or no. (%) unless otherwise indicated. OR, odds ratio; CI, confidence interval; NA, not applicable; CT, computed tomography; TTP, time to positive blood culture; ESBL, extended-spectrum β-lactamase.
†For K1 group, 24 patients; for K2 group, 25 patients; for non–K1/K2 group, 93 patients.
